The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma-Reference-Cited by-同舟云学术

The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma

Published:2019-08-28 Issue:4 Volume:38 Page:956-966
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Li Xi’an,Hou Guangdong,Zhu Zheng,Yan Fei,Wang Fuli,Wei Di,Zheng Yu,Yuan Jiarui,Zheng Wanxiang,Zhang Geng,Meng Ping,Guo Yan,Li Xia,Yao Libo,Shen Lan^ORCID,Yuan Jianlin

Funder

Major Research Plan

Young Scientists Fund

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00839-8.pdf

Reference22 articles.

1. Linehan WM, Srinivasan R, Schmidt LS (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7(5):277–285. https://doi.org/10.1038/nrurol.2010.47

2. Kaelin WG Jr (2007) The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13(2 Pt 2):680s–684s. https://doi.org/10.1158/1078-0432.CCR-06-1865

3. Pal SK, Quinn DI (2013) Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev 39(7):709–719. https://doi.org/10.1016/j.ctrv.2012.12.015

4. Cardillo TM, Trisal P, Arrojo R, Goldenberg DM, Chang CH (2013) Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer 13:170. https://doi.org/10.1186/1471-2407-13-170

5. Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S, Han H, Nie X, Li Q, Kung HF, Leung SY, Lin MC (2003) N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 106(3):342–347. https://doi.org/10.1002/ijc.11228

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NDRG2 regulates glucose metabolism and ferroptosis of OGD/R‐treated astrocytes by the Wnt/β‐catenin signaling;Journal of Biochemical and Molecular Toxicology;2024-08-28

2. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade;Toxicology and Applied Pharmacology;2024-04

3. Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial;Clinical Cancer Research;2022-05-16

4. Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma;Journal of Cancer;2022

5. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma;PLOS ONE;2021-11-03